These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9538519)

  • 21. Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP.
    Siragy HM; El-Kersh MA; De Gasparo M; Webb RL; Carey RM
    J Hypertens; 2002 Jun; 20(6):1157-63. PubMed ID: 12023686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Nonpeptide angiotensin II antagonists].
    Shionoiri H; Takasaki I; Sugimoto K; Minamisawa K
    Nihon Rinsho; 1992 Apr; 50 Suppl():753-63. PubMed ID: 1635263
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
    Berellini G; Cruciani G; Mannhold R
    J Med Chem; 2005 Jun; 48(13):4389-99. PubMed ID: 15974591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives.
    Bühlmayer P; Criscione L; Fuhrer W; Furet P; de Gasparo M; Stutz S; Whitebread S
    J Med Chem; 1991 Oct; 34(10):3105-14. PubMed ID: 1920360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism.
    Haddad G; Amiri F; Garcia R
    Regul Pept; 1997 Jan; 68(2):111-7. PubMed ID: 9110382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative molecular field analysis and molecular modelling studies on pyridylimidazole type of angiotensin II antagonists.
    Yoo SE; Kim SK; Lee SH; Yi KY; Lee DW
    Bioorg Med Chem; 1999 Dec; 7(12):2971-6. PubMed ID: 10658603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An exploration of a novel strategy for superposing several flexible molecules.
    Perkins TD; Dean PM
    J Comput Aided Mol Des; 1993 Apr; 7(2):155-72. PubMed ID: 8320554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
    Mazzolai L; Maillard M; Rossat J; Nussberger J; Brunner HR; Burnier M
    Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors.
    Inada Y; Nakane T; Chiba S
    Fundam Clin Pharmacol; 2002 Aug; 16(4):317-23. PubMed ID: 12570021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Losartan. The first non-peptide angiotensin II receptor antagonist for treatment of hypertension].
    Ibsen H; Rasmussen S; Slatanach R
    Ugeskr Laeger; 1996 Jun; 158(26):3798-802. PubMed ID: 8686080
    [No Abstract]   [Full Text] [Related]  

  • 31. KT3-671, an angiotensin AT1 receptor antagonist, attenuates vascular but not cardiac responses to sympathetic nerve stimulation in pithed rats.
    Takata Y; Kurihara J; Yoda T; Suzuki S; Matsuoka Y; Okubo Y; Kato H
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):427-36. PubMed ID: 11300656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin II receptor inhibition. A new therapeutic principle.
    Messerli FH; Weber MA; Brunner HR
    Arch Intern Med; 1996 Sep; 156(17):1957-65. PubMed ID: 8823149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure elucidation and conformational study of V8: a novel synthetic non peptide AT(1) antagonist.
    Zoumpoulakis P; Politi A; Grdadolnik SG; Matsoukas J; Mavromoustakos T
    J Pharm Biomed Anal; 2006 Mar; 40(5):1097-104. PubMed ID: 16260110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Competitive antagonism of pressor responses to angiotensin II and angiotensin III by the angiotensin II-1 receptor ligand losartan.
    Abdelrahman A; Pang CC
    Can J Physiol Pharmacol; 1992 May; 70(5):716-9. PubMed ID: 1423014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
    Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
    Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Molecular biology of angiotensin II receptor and clinical application of the antagonist].
    Hiwada K
    Nihon Naika Gakkai Zasshi; 1994 Jan; 83(1):143-8. PubMed ID: 9132445
    [No Abstract]   [Full Text] [Related]  

  • 37. Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan.
    Shetty SS; DelGrande D
    J Pharmacol Exp Ther; 2000 Jul; 294(1):179-86. PubMed ID: 10871310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of angiotensin II and antagonists on AT(1) receptor expression in mesangial cells.
    Chansel D; Vandermeersch S; Llorens-Cortes C; Ardaillou R
    Eur J Pharmacol; 1999 Nov; 384(2-3):223-30. PubMed ID: 10611445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efforts to understand the molecular basis of hypertension through drug:membrane interactions.
    Mavromoustakos T; Zoumpoulakis P; Kyrikou I; Zoga A; Siapi E; Zervou M; Daliani I; Dimitriou D; Pitsas A; Kamoutsis C; Laggner P
    Curr Top Med Chem; 2004; 4(4):445-59. PubMed ID: 14965311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin II enhances integrin and alpha-actinin expression in adult rat cardiac fibroblasts.
    Kawano H; Cody RJ; Graf K; Goetze S; Kawano Y; Schnee J; Law RE; Hsueh WA
    Hypertension; 2000 Jan; 35(1 Pt 2):273-9. PubMed ID: 10642310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.